DIA 48th Annual Meeting
Click here to go to the previous page
Challenges and Opportunities for Drug Development in China
Track
:
Track 08: Regulatory Affairs and Submissions
Program Code:
137
Date:
Monday, June 25, 2012
Time:
1:30 PM to 3:00 PM
EST
CHAIR
:
Laura Hong, SAPA (Sino-American Pharmaceutical Professionals Association), United States
PRESENTER
(S):
Zhongda Zhang, Pharmaron, Inc.
Yinxiang Wang, Zhejiang Beta Pharma Inc., China
Dayao Zhao, Johnson & Johnson, China
Description
This session will provide enriched discussions on the current status and unique challenges for drug development in China, the increasing role of China in global development of drug products, and opportunities for China's SFDA and pharmaceutical industry to improve, succeed, and excel. This session is hosted by Sino-American Pharmaceutical Professionals Association (SAPA).
Learning Objectives:
Recognize current status and unique challenges for drug development in China
Discuss the role of China in the development of drug products.
Learning Objectives:
Recognize current status and unique challenges for drug development in China
Discuss the role of China in the development of drug products.
This session is a part of:
Handout Online
